PATENT CLAIM ANALYSIS

Application Number: 15939822
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "298000"]

Abstract:
This invention relates to the use of low doses of (+)-α-dihydrotetrabenazine for the treatment of movement disorders, such as Tourette's syndrome.

Claim (Index 1):
A method of treating a movement disorder in a subject in need thereof, which treatment comprises the steps of:\n (a) administering to the subject an initial daily dosage of (+)-\u03b1-dihydrotetrabenazine or pharmaceutically acceptable salt thereof, wherein the initial daily dosage is an amount of (+)-\u03b1-dihydrotetrabenazine or pharmaceutically acceptable salt thereof corresponding to from 0.5 mg to 5 mg of (+)-\u03b1-dihydrotetrabenazine free base; (b) carrying out a clinical evaluation of the subject for efficacy and side effects arising from the treatment; (c) where the clinical evaluation (b) has established that an increased daily dosage of (+)-\u03b1-dihydrotetrabenazine or pharmaceutically acceptable salt thereof is desirable, administering an increased daily dosage which is greater than the initial daily dosage by an incremental amount of (+)-\u03b1-dihydrotetrabenazine or pharmaceutically acceptable salt thereof corresponding to from 0.5 mg to 5 mg of (+)-\u03b1-dihydrotetrabenazine free base; or, where the clinical evaluation has established that an increased daily dosage is not desirable, either maintaining the initial daily dosage, reducing the dosage, or discontinuing the treatment; (d) where an increased daily dosage has been administered, carrying out a further clinical evaluation of the subject for efficacy and side effects arising from the treatment with the increased daily dosage; (e) where the further clinical evaluation (d) has established that a further increased daily dosage of (+)-\u03b1-dihydrotetrabenazine or pharmaceutically acceptable salt thereof is desirable, administering a further increased daily dosage which is greater than an immediately preceding daily dosage by an incremental amount of (+)-\u03b1-dihydrotetrabenazine or pharmaceutically acceptable salt thereof corresponding to from 0.5 mg to 5 mg of (+)-\u03b1-dihydrotetrabenazine free base; or, where the clinical evaluation has established that a further increased daily dosage is not desirable, maintaining the immediately preceding daily dosage, reducing the immediately preceding dosage or discontinuing the treatment; and (f) optionally repeating steps (d) and (e) as often as desired until an optimum daily dosage is reached.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15939826', '15939837', '12555695', '14442996', '15629314']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7889707110072067
- 35 USC 102 Novelty (BERT): 0.6189816729143913
- Combined Prediction Score: 0.7719718071979252
- Mean Citation Score: 434.760146
- Max Citation Score: 659.07886
- Similarity Product: 470.59785376823424

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test